Ibrutinib (Imbruvica)

Type: drug

Status: FDA Approved

Developer: Pharmacyclics (now AbbVie) and Janssen Biotech

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026